TY  - JOUR 
AU  - García Campelo, María del Rosario
PY  - 2015
SN  - 0923-7534
UR  - http://hdl.handle.net/20.500.11940/3872
LA  - eng
TI  - A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease
T2  - ANNALS OF ONCOLOGY
M2  - 146
VL  - 26
ER  -